BioSpace News Archive

Guardion Health Sciences, Inc., a company that has developed medical foods and medical devices in the ocular health marketplace and is developing condition-specific nutraceuticals that the Company believes will provide supportive health benefits to consumers, announced its financial results for the quarter ended March 31, 2020.

Company has sufficient capital to advance pipeline and fund operations through 2021

Prevail Therapeutics Inc., a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, reviewed recent business highlights and reported financial results for the first quarter ended March 31, 2020.

INOVIO (NASDAQ: INO) today announced that 85 percent (44 out of 52) of patients newly diagnosed with the deadly brain cancer glioblastoma multiforme (GBM) who received the company’s DNA medicine INO-5401, in combination with INO-9012 and PD-1 inhibitor Libtayo® (cemiplimab), were alive for at least 12 months or more (overall survival at 12 months: OS12) following treatment

C-Level Speakers from The Centers for Disease Control, Cleveland Clinic, U.S. Army, Accenture, Biogen, The NBA’s Boston Celtics, State of Florida, BMO and other Top Organizations to Discuss How to Return to Work, Utilize Contact Tracing and Manage Operations to Best Mitigate the Risk of COVID-19.

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that data from the Phase 1 study of SRF231, a fully human, high-affinity anti-CD47 antibody, will be presented at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting, to be held virtually May 29-31. A summary is provided below; the full poster will be

Collaboration to Study Immuno-STAT Biologics on T Cell Immunological Synapse Formation Using the IL-2-Based CUE-100 Series

Continued high rate of SVR35 in 1L patients: 72% at 12 weeks and 67% at 24 weeks SVR35 responses and transfusion dependence conversion observed in 2L monotherapy patients Improvement in bone marrow fibrosis seen across treatment arms Additional data to be presented at EHA from ~50 1L and 70-80 2L patients CAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that three abstracts relating to the MANIFEST clinical tr

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the first quarter ended March 31, 2020 and provided a company update.

Data obtained in real-life setting from more than 800 patients with node-negative or node-positive early-stage breast cancer highlight the test’s impact on clinical practice with chemotherapy-sparing effect